Compares empagliflozin and metformin for type 2 diabetes in newly treated adults
Compares two diabetes medicines, empagliflozin and metformin, in adults newly starting treatment.
Key facts
- Who runs it
- Seoul National University Bundang Hospital
- Where
- Seongnam, South KoreaSee the site
- Trial code
- Registry title
- The EMPA-FIT Study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 46 people, planned
- Started
- 1 Jan 2024
- Planned end
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Empagliflozin 10 mg
- Metformin
- Record updated
- 26 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who have never taken diabetes medicine. They would take empagliflozin or metformin for 12 weeks.
- Age
- 20 to 75 years.
- Sex
- Men and women can join.
- Disease stage
- Type 2 diabetes with an HbA1c between 6.5% (48 mmol/mol) and 10.0% (86 mmol/mol).
- Earlier treatment
- No diabetes medicine for at least eight weeks before screening.
- Biomarker or test result
- HbA1c between 6.5% (48 mmol/mol) and 10.0% (86 mmol/mol).
Main reasons for not taking part
- BMI below 18.5 kg/m² or 40 kg/m² and above
- Serious liver problems such as cirrhosis or portal hypertension
- Heart or blood vessel event within the last two months
- Kidney disease with eGFR below 60 mL/min/1.73 m², or on dialysis
- Cancer in the past five years, except basal cell carcinoma
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants were eligible if they had T2D with an HbA1c between 6.5% and 10.0%, were between 20 and 75 years of age, and had not received any anti-diabetic medications for at least eight weeks prior to screening
Who cannot take part
- individuals with a body mass index (BMI) <18.5 kg/m² or ≥40 kg/m², clinically significant hepatic impairment (e.g., hepatic cirrhosis, portal hypertension, chronic active hepatitis), or a history of acute cardiovascular events (e.g., coronary artery disease, cerebrovascular disease, peripheral arterial disease) within two months prior to enrollment. Participants with CKD (eGFR <60 mL/min/1.73 m²) or end-stage renal disease (eGFR <15 mL/min/1.73 m² or on dialysis) were also excluded; Additional exclusion criteria included uncontrolled hypertension (BP ≥160/100 mmHg), New York Heart Association (NYHA) class III or IV heart failure, chronic oral corticosteroid use (>30 consecutive days), a history of cancer (except basal cell carcinoma) within the past five years, or significant dyslipidemia (triglycerides >1,000 mg/dL or LDL cholesterol >250 mg/dL)
Where in South Korea
- SNUBHSeongnam, South KoreaContact: Soo Lim, MD.Taking people
About the trial
What the trial wants to find out
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
The 2 groups in the trial
- StandardExisting treatment, for comparison
Metformin therapy
Treatment: Metformin
- ExperimentalTreatment being tested
Empagliflozin therapy
Treatment: Empagliflozin 10 mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Empagliflozin Versus Metformin for Glucose Variability and Metabolic Outcomes in Drug-Naïve Type 2 Diabetes
- Plain-language title
- Compares empagliflozin and metformin for type 2 diabetes in newly treated adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 February 2025